NICE Guidance on Bevacizumab for Metastatic Colorectal Cancer (TA1136)

NICE Technology Appraisals

Published February 25th, 2026

Detected March 12th, 2026

Summary

NICE has published updated technology appraisal guidance (TA1136) on the use of bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. This guidance replaces previous recommendations and provides evidence-based recommendations for healthcare professionals.

View original document View source feed page

What changed

NICE has issued updated technology appraisal guidance TA1136, which provides evidence-based recommendations on the use of bevacizumab (both originator and biosimilar versions) in combination with fluoropyrimidine-based chemotherapy for the treatment of metastatic colorectal cancer. This guidance supersedes previous NICE guidance on the topic, including TA212, and partially updates TA242 and TA118. It outlines the clinical and economic considerations for the use of this treatment regimen.

Healthcare professionals are expected to consider this guidance when making treatment decisions, alongside patient needs and preferences. While the guidance itself is non-binding, commissioners and providers are responsible for ensuring funding is available. The document also highlights the importance of reporting adverse events via the Yellow Card Scheme and encourages consideration of environmental sustainability in implementation.

What to do next

Review updated NICE guidance TA1136 regarding bevacizumab for metastatic colorectal cancer.
Incorporate recommendations into clinical decision-making processes for eligible patients.
Ensure appropriate funding mechanisms are in place for recommended treatments.

Source document (simplified)

Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

Technology appraisal guidance
TA1136
Published:

25 February 2026

Download guidance (PDF)

Overview

Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Last reviewed: 25 February 2026

This guidance updates and replaces NICE's technology appraisal guidance 212 on bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer.

It also partially updates NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118).

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

Regionally available price reductions for bevacizumab (originator and biosimilars) are in place with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence.

Guidance development process

How we develop NICE technology appraisal guidance

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.